Literature DB >> 8946173

A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria.

A Fontanellas1, M Bensidhoum, R Enriquez de Salamanca, A Moruno Tirado, H de Verneuil, C Ged.   

Abstract

Congenital erythropoietic porphyria (CEP) or Günther's disease is an inborn error of heme biosynthesis, transmitted as an autosomal recessive trait and characterized by a profound deficiency of uroporphyrinogen III synthase activity (UROIIIS). The molecular defects observed in CEP are mainly heterogeneous, except for one missense mutation, C73R (Cys to Arg substitution at codon 73) which represents nearly 40% of the disease alleles. A convenient strategy was designed to establish a rapid diagnosis at the genetic level in samples from patients with CEP. As a first step, the most frequent mutation is searched for by restriction analysis from genomic. DNA amplified by PCR. Next, the nine coding exons and intron-exon boundaries are sequenced from genomic DNA. As an alternative, the mutation can be determined by sequencing the UROIIIS cDNA of the patient, using the RT-PCR technique on RNAs when a lymphoblastoid cell line can be established. Finally, for each new mutation in UROIIIS coding sequence, the corresponding mutant protein is expressed in Escherichia coli, in order to demonstrate the pathological significance of the mutation. This work describes the analysis of UROIIIS gene mutations in 10 new families with CEP and summarizes the data from 20 unrelated families studied in our laboratory. Three new missense mutations of UROIIIS coding sequence (H173Y, Q187P and P248Q) have been observed together with 8 known mutations. The significance of three intronic base changes (476 -31 T-->C; 562 -4 A-->T; 562 -23 A-->G) is discussed. In 6 alleles out of 40 (15%), the mutation remains undetermined.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946173     DOI: 10.1159/000472214

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  10 in total

1.  Intracellular rescue of the uroporphyrinogen III synthase activity in enzymes carrying the hotspot mutation C73R.

Authors:  Arola Fortian; Esperanza González; David Castaño; Juan M Falcon-Perez; Oscar Millet
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

2.  Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria.

Authors:  F Mazurier; F Moreau-Gaudry; S Salesse; C Barbot; C Ged; J Reiffers; H de Verneuil
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

3.  Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria.

Authors:  C Solis; G I Aizencang; K H Astrin; D F Bishop; R J Desnick
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

4.  Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease).

Authors:  Sophie Dupuis-Girod; Véronique Akkari; Cécile Ged; Claire Galambrun; Kamila Kebaïli; Jean-Charles Deybach; Alain Claudy; Lucette Geburher; Noël Philippe; Hubert de Verneuil; Yves Bertrand
Journal:  Eur J Pediatr       Date:  2004-11-20       Impact factor: 3.183

5.  Mutational analysis of uroporphyrinogen III cosynthase gene in Iranian families with congenital erythropoietic porphyria.

Authors:  Meysam Moghbeli; Mahmood Maleknejad; Azadeh Arabi; Mohammad Reza Abbaszadegan
Journal:  Mol Biol Rep       Date:  2012-02-18       Impact factor: 2.316

6.  Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions.

Authors:  David F Bishop; Annika Johansson; Robert Phelps; Amr A Shady; Maria C M Ramirez; Makiko Yasuda; Andres Caro; Robert J Desnick
Journal:  Am J Hum Genet       Date:  2006-02-09       Impact factor: 11.025

7.  Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells.

Authors:  F Géronimi; E Richard; I Lamrissi-Garcia; M Lalanne; C Ged; I Redonnet-Vernhet; F Moreau-Gaudry; H de Verneuil
Journal:  J Mol Med (Berl)       Date:  2003-04-30       Impact factor: 4.599

8.  Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

Authors:  Elodie Robert-Richard; François Moreau-Gaudry; Magalie Lalanne; Isabelle Lamrissi-Garcia; Muriel Cario-André; Véronique Guyonnet-Dupérat; Laurence Taine; Cécile Ged; Hubert de Verneuil
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

Review 9.  Congenital erythropoietic porphyria: Recent advances.

Authors:  Angelika L Erwin; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2018-12-27       Impact factor: 4.797

Review 10.  Clinically important features of porphyrin and heme metabolism and the porphyrias.

Authors:  Siddesh Besur; Wehong Hou; Paul Schmeltzer; Herbert L Bonkovsky
Journal:  Metabolites       Date:  2014-11-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.